EMPULSE study
- United States
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 percent in adults with and without diabetes who had heart failure with reduced ejection fraction
Ingelheim, Germany & Indianapolis, United States: Empagliflozin also significantly reduced the relative risk of first and recurrent hospitalization for heart…
Read More »